Yeah, I mean, the only thing I would like to add about MANIFEST-2, because sometimes I think it’s easy to forget about a study that completed its primary endpoint, but that study has continued to be followed out. And I just want to impress upon the viewers that that’s still the largest upfront randomized prospective study with this kind of follow-up. It’s going to be week 144 soon...
Yeah, I mean, the only thing I would like to add about MANIFEST-2, because sometimes I think it’s easy to forget about a study that completed its primary endpoint, but that study has continued to be followed out. And I just want to impress upon the viewers that that’s still the largest upfront randomized prospective study with this kind of follow-up. It’s going to be week 144 soon. That’s a wealth of information and data. And what you see already at 96 weeks is the durability of spleen response. So although the primary data set that the core data at week 24 showed doubling of SVR and a two-point difference in that absolute change in TSS that was just barely statistical or just missed statistical significance. I would argue it’s the durability of that spleen response that probably is the most meaningful part of that data set in the longer-term follow-up. Because the short-term follow-up at 24 weeks is a regulatory endpoint. But what really matters when you treat the patients is can you maintain that response? Because we have five different data sets at this point that tell us that if you lose that response and come off treatment, your outcome is poor. So the fact that you see this durability at 96 weeks and we’re going to see 144 weeks, that speaks volumes. And I think that still makes Palbociclib an important agent in clinical development.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.